Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.CTQLEHs_.js ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $328 from $322 and keeps an Equal Weight rating on the ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...